ADAR1 Capital Management »

Apellis Pharmaceuticals shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Apellis Pharmaceuticals (APLS) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Apellis Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Apellis Pharmaceuticals held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Apellis Pharmaceuticals by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $1.5M 26k 58.78

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Apellis Pharmaceuticals

EcoR1 Capital
Vanguard Group
BlackRock
BlackRock
State Street Corporation
Jpmorgan Chase & Co
Braidwell
Octagon Capital Advisors
T. Rowe Price Investment Management
Deep Track Capital
Logos Global Management
Siren
Assenagon Asset Management
Morgan Stanley
Jennison Associates

View all funds holding Apellis Pharmaceuticals